Elysium Health will make six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500—available through its prescription arm under an interim enforcement-discretion policy from the U.S. Department of Health and Human Services that permits limited compounding under defined conditions. The company is concurrently launching a controlled-supply research resource for qualified institutions and a study examining epigenetic changes and biological age measures. Compounded drugs are not FDA-reviewed for safety, effectiveness or quality, and the company acknowledges human clinical evidence for these compounds remains limited.
Key Points
- Six peptides move to prescription access under HHS enforcement-discretion policy
- Compounded products remain outside FDA review for safety and quality
- Planned study will track epigenetic age markers and mortality associations
Longevity Analysis
Peptides occupy a category where mechanistic plausibility outpaces human outcome data: tissue repair, mitochondrial signaling, inflammatory modulation and neuroendocrine rhythm each have compelling preclinical rationale, yet dosing, duration and long-term safety remain largely uncharacterized in people. The regulatory shift widens access without supplying the evidence that would justify it, which places the burden of discrimination on prescribing physicians and on patients willing to interpret their own biomarkers over time. Commitment to epigenetic age tracking and adverse-event reporting is the more consequential development here—measurement is what converts an unproven intervention into a decision that can be revised.
Original published by LT Wire.